Every 8-K that Alector, Inc. (ALEC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALEC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALEC filings page.
Alector, Inc. reported second quarter 2026 results and updated progress across its Alector Brain Carrier (ABC) blood-brain barrier platform. Collaboration revenue for the quarter ended June 30, 2026 was $3.3 million, down from $7.9 million a year earlier. Research and development expenses decreased to $19.5 million from $27.6 million, and general and administrative expenses declined to $8.3 million from $14.4 million, reflecting prior reductions in force and lower facilities and other costs. Net loss narrowed to $23.0 million, or $0.21 per share, compared with a net loss of $30.5 million, or $0.30 per share, in the 2025 quarter.
As of June 30, 2026, cash, cash equivalents and investments totaled $172.8 million, and management anticipates this will fund operations at least through 2027. The company highlighted advancement of AL137 as its lead ABC-enabled anti-amyloid beta antibody for Alzheimer’s disease, targeting an IND submission in Q1 2027 and first-in-human dosing in Australia no later than April 2027, alongside ongoing work on ABC-enabled siRNA programs AL064/AL164 and enzyme replacement therapy candidate AL050 for Parkinson’s disease.
Alector, Inc. reported that Glaxo Wellcome UK Limited (GSK) has elected to terminate their July 2021 collaboration and license agreement covering the progranulin-elevating antibodies latozinemab and nivisnebart. Under the agreement, the termination becomes effective 180 days after GSK’s July 6, 2026 notice, on January 2, 2027.
The filing links this decision to prior announcements that the Phase 3 INFRONT-3 trial of latozinemab in frontotemporal dementia and the Phase 2 PROGRESS-AD trial of nivisnebart in early Alzheimer’s disease were discontinued after not meeting key clinical goals. Alector also fully repaid and terminated its Loan and Security Agreement with Hercules Capital, returning $10,428,827.77 of outstanding principal plus accrued interest and related charges on July 8, 2026.
Alector, Inc. reported the results of its 2026 annual meeting of stockholders. Shareholders elected three Class II directors—Elizabeth Garofalo, M.D., Errol De Souza, Ph.D., and Kristine Yaffe, M.D.—to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also ratified Ernst & Young LLP as Alector’s independent registered accounting firm for the fiscal year ending December 31, 2026, with 97,717,750 votes in favor. In addition, shareholders approved, on a non-binding advisory basis, the compensation of Alector’s named executive officers in the Say-on-Pay vote, with 58,652,335 votes for and 2,492,538 against.
Alector, Inc. entered into a new Sales Agreement with TD Securities (USA) LLC that allows it to offer and sell up to $125,000,000 of common stock through an at-the-market program under its effective shelf registration.
Shares may be sold from time to time on The Nasdaq Global Select Market or through other permitted methods, with Alector setting parameters such as timing, share amounts, daily limits, and minimum prices. TD Cowen may receive up to 3.0% of the gross sales price as compensation. Alector plans to use any net proceeds for general corporate purposes, including research, development and manufacturing of product candidates, working capital, capital expenditures, other corporate expenses, and potential acquisitions or strategic transactions.
Alector, Inc. reported first quarter 2026 results and outlined a strategic shift toward its Alector Brain Carrier (ABC) platform after ending a key Alzheimer’s trial. Collaboration revenue was $1.0 million versus $3.7 million a year earlier as work supporting the nivisnebart Phase 2 study wound down.
Research and development expenses fell to $17.9 million from $33.6 million, and general and administrative expenses declined to $8.1 million from $14.7 million, reflecting prior reductions in force. Net loss narrowed to $22.9 million, or $0.21 per share, compared with $40.5 million, or $0.41 per share, in 2025.
Cash, cash equivalents, and investments totaled $206.5 million as of March 31, 2026, which management expects will fund operations at least through 2027. The company is advancing multiple ABC-enabled preclinical programs in Alzheimer’s and Parkinson’s disease while the global Phase 2 PROGRESS-AD trial of nivisnebart was discontinued after a pre-specified interim futility analysis.
Alector, Inc. reported fourth quarter and full year 2025 results and highlighted progress across its neurodegeneration pipeline and Alector Brain Carrier (ABC) platform. Collaboration revenue fell to $6.2 million in the quarter and $21.0 million for the year, down sharply from $54.2 million and $100.6 million in 2024, mainly due to completing prior collaboration milestones.
Research and development expenses declined to $123.1 million for 2025 from $185.9 million, and general and administrative expenses decreased to $54.0 million from $59.6 million, reflecting prior reductions in force. Despite lower spending, the 2025 net loss widened to $142.9 million, or $1.39 per share, compared with a $119.0 million loss, or $1.23 per share, in 2024.
The company ended 2025 with $256.0 million in cash, cash equivalents, and investments and expects this to fund operations at least through 2027, while advancing programs including AL137, AL050, AL064, and the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) with an interim futility analysis planned in the first half of 2026.
Alector, Inc. has appointed Neil Berkley as its Chief Financial Officer, effective December 10, 2025. He had been serving as Interim Chief Financial Officer since June 2025.
Mr. Berkley will continue in his role as Chief Business Officer and remains Alector’s principal financial officer. The company reports that there are no changes to his existing compensatory arrangements in connection with this appointment. Alector issued a press release about the appointment on December 12, 2025, which is included as Exhibit 99.1.
Alector, Inc. furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company provided a press release detailing these results, attached as Exhibit 99.1.
The information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and not deemed “filed” under the Exchange Act. The filing also includes Exhibit 104 containing the cover page Inline XBRL tags.
Alector, Inc. (ALEC) announced a major restructuring tied to outcomes from its Phase 3 INFRONT-3 trial of latozinemab (AL001) in FTD-GRN. The company will reduce its workforce by approximately 49%, affecting about 75 employees, and will discontinue the open-label extension portion of INFRONT-3 as well as the continuation study for latozinemab.
Total incremental restructuring charges are expected to be about $7.7 million, primarily for severance and related termination benefits. Cash payments are expected to be paid out and the reduction in force completed during the first half of 2026. The company noted these estimates are subject to assumptions and may change.
Leadership update: Sara Kenkare-Mitra, Ph.D., President and Head of R&D, will resign effective December 22, 2025. Under a separation agreement, she will receive a lump-sum equal to nine months of base salary, a payment equal to 50% of her annual bonus target, and nine months of company-paid COBRA premiums. Alector also issued a press release with INFRONT-3 data results that included a preliminary estimate of cash, cash equivalents, and short-term investments as of September 30, 2025.